Get started
Author

Inma Blasco

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2012 · Andres Cervantes, Elena Elez, et al. · Clinical Cancer Research · 153
Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics
2010 · Teresa Macarulla, Andres Cervantes, et al. · Molecular Cancer Therapeutics · 88
PDF
Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study
2021 · Valentina Gambardella, Pasquale Lombardi, et al. · British Journal of Cancer · 33
PDF
Supplementary Tables 1 - 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
PDF
Supplementary Methods from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
PDF
Supplementary Figure 2 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Figure 3 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Figure 5 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Figure 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Figure 1 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
PDF
Supplementary Tables 1 - 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Methods from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Figure 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
PDF
Supplementary Figure 1 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Figure 2 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
PDF
Supplementary Figure 3 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
PDF
Data from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Data from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Figure 5 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
PDF
Works count: 19
Citation count: 274
H-index: 3
I10-index: 3
Year
Topic
Type